

2009 Research Days Abstract Form – Department of Ophthalmology – UNIFESP/EPM

2] SCIENTIFIC SECTION PREFERENCE (REQUIRED):

Review the Scientific Section Descriptions. Select and enter the two-letter Code for the one (1) Section best suited to review your abstract.

3. PRESENTATION PREFERENCE (REQUIRED) Check one:

- Paper
- Poster
- FAST Paper

4. The signature of the First (Presenting) Author (REQUIRED) acting as the authorized agent for all authors, hereby certifies that any research reported was conducted in compliance with the Declaration of Helsinki and the "UNIFESP Ethical Committee"

Scientific Section Descriptions (two-letter code):

- (BE) OCULAR BIOENGINEERING
- (CO) CORNEA AND EXTERNAL DISEASE
- (CA) CATARACT
- (EF) ELECTROPHYSIOLOGY
- (EP) EPIDEMIOLOGY
- (EX) EXPERIMENTAL SURGERY
- (GL) GLAUCOMA
- (LA) LABORATORY
- (LS) LACRIMAL SYSTEM
- (LV) LOW VISION
- (NO) NEURO-OPHTHALMOLOGY
- (OR) ORBIT
- (PL) OCULAR PLASTIC SURGERY
- (PH) PHARMACOLOGY
- (RE) RETINA AND VITREOUS
- (RS) REFRACTIVE SURGERY
- (RX) REFRACTION-CONTACT LENSES
- (ST) STRABISMUS
- (TR) TRAUMA
- (TU) TUMORS AND PATHOLOGY
- (UV) UVEITIS
- (US) OCULAR ULTRASOUND

Deadline: Oct 12, 2009

FORMAT:
Abstract should contain:
Title
Author, Co-authors (maximum 6),
Purpose, Methods, Results,
Conclusion.

Poster guidelines:
ARVO Abstract Book (1.10 x 1.70m)

119. FIRST (PRESENTING) AUTHOR (REQUIRED):

Must be the author listed first in abstract body.

- () R1 () R2 (X) R3 () PIBIC
- () PG0 () PG1 () Fellow () Technician

Last Name: Sarraff
First Name: Eduardo
Middle: Pantaleão

Service (Sector): OCULAR PLASTIC SURGERY

CFP Number: 1205/09

Formatados: Marcadores e numeração

EVALUATION OF DEPRESSION AND ANXIETY BEFORE AND AFTER BOTULINUM TOXIN TYPE A TREATMENT IN FACIAL DYSTONIA PATIENTS.

Authors: Sarraff EP, Osaki TH, Hossaka SK, Pereira CI, Miyazato PY, Cariello AJ, Osaki MH.

Purpose: To evaluate the depression and anxiety level using Hospital Anxiety and Depression Scale (HADS) before and after botulinum toxin type A injection in patients with facial dystonia.

Methods: Patients with facial dystonia who have indication for botulinum toxin treatment were included. All patients were invited to answer the HADS before and one month after botulinum toxin treatment. The questionnaire was applied by the same examiner. The HADS score was analyzed and compared before and after botulinum toxin treatment.

Results: The results are still in progress.

Conclusions: We expect that the treatment improves the symptoms of anxiety and depression in patients with facial dystonia.